Christian U. Blank, MD, PhD, on Clinical Implications of New Findings on Neoadjuvant Nivolumab Plus Ipilimumab in Melanoma

Posted: Tuesday, June 11, 2024

Christian U. Blank, MD, PhD, of the Netherlands Cancer Institute, discusses phase III findings from the investigator-initiated NADINA trial showing that, for patients with macroscopic, resectable stage III melanoma, neoadjuvant ipilimumab plus nivolumab followed by response-driven adjuvant treatment improved event-free survival compared with adjuvant nivolumab.

---